building a quality mindset with your partner to ... t4-2_hung... · your partner to manufacture...
TRANSCRIPT
Building a Quality Mindset with Your Partner to Manufacture Safe Clinical Materials
The 3rd DIA China Annual Meeting Quality & Standards – Elevating China Pharmaceutical Development
Hung-Chih Chang, Ph.D.Director, Product R&D
May 15-18, 2011
Agenda
• Background
• Collaboration Started with Process Chemistry to GMP API Manufacture in China
05/17/2011 HC Chang
The 3rd Drug Information Association China Annual Meeting 2
• Partnership is Expanding to Finished Product Manufacture for FHD
• Building a Quality Mindset through the Qualification of CT Manufacturing Facility
• Summary
Background
To reach clinical proof-of-concept more quickly and cost effectively than traditional R&D approaches :• Transforming from FIPCO to FIPNET
• Fully Integrated Pharmaceutical Co
US
05/17/2011 HC Chang
The 3rd Drug Information Association China Annual Meeting 3
“source all, own all, do all at our cost structure”
• Fully Integrated Pharmaceutical Network
“many sources across the globe, share financial risk & rewards, and share work”
• Build external R&D network to manage capacity overflow for early-phase development
• Allow internal resource to focus on late-stage development
• Access global technical expertise
AsiaEU
Background (cont’d)
Why offshoring the clinical supply chain (preformulation, formulation development, CT manufacturing and packaging ) to the emerging markets? • Shift clinical research from traditional developed markets
to emerging markets• Recruitment rates are higher
• Competition for patients is lower
• Align CT material supply close to the sites of clinical trials • Eliminate import hurdles
• Increase speed
• Support local trials and expedite local drug registration
• 14-17% growth in Pharmerging markets thro’ 2014 vs. 3-6% in developed markets
05/17/2011 HC Chang
The 3rd Drug Information Association China Annual Meeting 4
External Collaboration to Enable Information Generation & Material Supply
Clinical MilestonesPreclinical Phase 1 Phase 2 Phase 3 Submission Launch
Supply API for Supply Phase 1 Supply Phase 2 Supply Phase 3 Resupply Phase 3
05/17/2011 HC Chang
The 3rd Drug Information Association China Annual Meeting 5
Information Generation
Developability Design Define Optimize Transfer
Material Supply
Supply API forToxicology
Supply Phase 1CT Materials
Supply Phase 2CT Materials
Supply Phase 3CT Materials
Resupply Phase 3CT Materials
Collaboration Started with Process Chemistry to GMP API Manufacture
• Initiated in 2004 • Process Chemistry • Building chemistry
blocks
• Set up a FTE program• 5 FTEs in 2006 – extension
to our in-house capabilities • API SMs, Intermediate• Laboratory Materials
• Helped to train the CORE group in the FTE program
• Building the technical expertise • Developed open communications
& business process
2004 2005/2006 2006
05/17/2011 HC Chang
The 3rd Drug Information Association China Annual Meeting 6
• Conducted quality due diligence at CRO’s cGMP APIfacility
• 12 FTEs in ProcessChemistry
• 6 FTEs in Analytical • Completed formal quality
audit for API in mid 2007
• Enhanced process chemistry knowledge & experience
• Building trust & quality mindset over years of collaboration
• Started to mfg cGMP intermediate & API in late 2007
2006 2007 2007/2008
Steps to Manufacture Quality GMP API
Lilly RFP CRO Quotation Lilly PO Order Materials
Process R&D in Lab• Evaluating the existing route• Optimization/Scaleability
To discuss:• Responsibility
GMP Campaign Kick Off• Process chemists from both sides
05/17/2011 HC Chang
The 3rd Drug Information Association China Annual Meeting 7
Analytical MethodDevelopment
Optimization/Scaleability• Safety assessment (e.g. RC-1)• Process details
• Agreement on analytical testing plan (ATP) for IPC & final release
ocess c e sts o bot s des• Analytical scientists from both sides• QA representative from both sides• Project Mgmt from both sides
cGMP Production
Lilly Scientists & QAare 24-hr on call during campaign
Testing per ATP
Send CoA,deviations, completed batch records to Lilly
Lilly Review &Approval
Building Quality Mindset with Your Partner
Continue to have mutual & open communications to improve partner’s overall QUALITY SYSTEM!
Gather Data
Analyze Data for
Major Investigation Step
05/17/2011 HC Chang
The 3rd Drug Information Association China Annual Meeting 8
For example, Lilly Dev. QA shared experience on “Performing Effective Investigation, Root Cause Analysis & Documenting Deviations” to our partner’s QA & technical staff.
Analyze Data for Causal Factors
Determine Root Causes
Develop Countermeasures
Partnership is Expanding to Drug Product Manufacture for FHD
• Initiated in 2004 • Process Chemistry • Building chemistry
blocks
• Set up a FTE program• 5 FTEs in 2006 – extension
to our in-house capabilities • API SMs, Intermediate• Laboratory Materials
• Helped to train the CORE group in the FTE program
• Building the technical expertise • Developed open communications
& business process
2004 2005/2006 2006
05/17/2011 HC Chang
The 3rd Drug Information Association China Annual Meeting 9
CRO built their cGMP CT mfg facility for drug product
Conducted quality due diligence at CRO’s cGMP APIfacility
• 12 FTEs in ProcessChemistry
• 6 FTEs in Analytical • Completed formal quality
audit for API in mid 2007
• Enhanced process chemistry knowledge & experience
• Building trust & quality mindset over years of collaboration
• Started to mfg cGMP intermediate & API in late 2007
2006 2007 2007/2008
Build Integrated CMC Capability with the Right Partner in China
After 3-Year’s collaboration:• CRO is building technical competence
• CRO is committed to strengthen quality system to provide quality GMP APIs
• Mutual trust, openness & spirit of collaboration
05/17/2011 HC Chang
The 3rd Drug Information Association China Annual Meeting 10
• A strategic partner to build CMC capabilities & integrate our FHD API & drug product manufacture
One global quality standard for Lilly materials whether manufactured internally or externally.
Lilly and the CMO/CRO are both fully
Quality Standard -Clinical Trial Material Manufacture
05/17/2011 HC Chang
The 3rd Drug Information Association China Annual Meeting 11
Lilly and the CMO/CRO are both fully responsible and accountable for Quality.
Quality is everyone’s responsibility.
Even though contract manufacturing of commercial products is now a well-established practice worldwide,
05/17/2011 HC Chang
The 3rd Drug Information Association China Annual Meeting 12
established practice worldwide, manufacturing clinical materials is NOT something that everybody is capable of handling.
Things to Consider When Selecting a Partner for Clinical Material Manufacture
• Containment Strategy• Material, personnel, and waste flows – prevent cross-
contamination• Operability of physical barriers (pressure cascades &
airlocks) and appropriate operation procedures designed to
05/17/2011 HC Chang
The 3rd Drug Information Association China Annual Meeting 13
) pp p p p greduce the risks of contamination
• Single-pass HVAC
• Cleaning Procedures• Cleaning validation will usually not be in place at this stage
but cleaning verification will be essential• Equipment Cleaning/Sanitization• Facility Cleaning/Sanitization
• Engineering Department • Is a skilled engineering department available to ensure the
flexibility of equipment, service, and utilities?• Willingness and ability to adapt custom design equipment • Have good contacts with local suppliers of small-scale GMP
equipment services and utilities
Things to Consider When Selecting a Partner for Clinical Material Manufacture
05/17/2011 HC Chang
The 3rd Drug Information Association China Annual Meeting 14
equipment, services and utilities
• Personnel Qualifications (QC & Technical)• Personnel have a thorough understanding of the application
of GMP to clinical trial (or IMPs) • QC unit – clear responsibility, adequate authority & staffing • Personnel qualifications
– Education, training, experience for manufacturing, packing, or holding of a drug product
– Operation Staff vs. Supervision
• Pharmaceutical Dosage Forms
• Drug-in-Bottle
• Drug-in-Capsule
• Direct-blend Capsule
Desired Capability to Manufacture Clinical Material for Early Trials
05/17/2011 HC Chang
The 3rd Drug Information Association China Annual Meeting 15
• Direct-blend Capsule
• Formulated Capsule
• Tablets
• Packaging (bottle & blister) and Labeling
• Analytical Testing and Release
• Bundling with GMP API manufacture is preferred
Outsourcing clinical material (finished products) manufacture in the Asia region is still developing. Our corporation is vigilant on this and very cautious in selecting the right
05/17/2011 HC Chang
The 3rd Drug Information Association China Annual Meeting 16
partner(s) to manufacture the SAFE clinical materials. Our development organization also realized that our internal technical functions and the development quality organization have to work together closely to ensure that the clinical materials get to the patients in a SAFE and timely manner.
In the very beginning of this journey, we clearly emphasized to our partner that the END GOAL is to produce QUALITY CLINICAL MATERIALS in a
h i f ll li i h i l
Building a Quality Mindset with Your Partner
QUALITY
05/17/2011 HC Chang
The 3rd Drug Information Association China Annual Meeting 17
manner that is fully compliant with our internal quality standard and all regulatory requirements.
It may take time but we are willingly to work with you on that if you choose to do so.
The Journey Has Begun……
Technical Capability
Assessment1st Quality
Due Diligence Formal
Quality Audit 3rd Quality
Due Diligence 2nd Quality
Due Diligence
2007 2008 2008 2008 2009
Technical EU QP Sr Mgmt of QA &Tech Org & EU QP & 3 US Auditors
05/17/2011 HC Chang
The 3rd Drug Information Association China Annual Meeting 18
Personnel (Quality Dir.) Tech Org & CT Personnel Dev QA 1 EU QP
Lilly Personnel Involvement
Purpose of the Visit
Discuss preferred mfg platform& equipment to produce clinical materials for FHDs
1. Understand the quality system
2. Assess if EU-equiv standards of GMP are applied.
1. Assess readiness for a formal QA audit from Lilly
2. Technical readiness
Assess readiness for a formal Lilly QA audit from both EU & US regulatory perspective.
Conduct formal Lilly QA audit
1st Quality Due Diligence
• Purpose:• To have a high level understanding of the CT manufacturing facility• To provide an overview of the European legislation (e.g. Annex 13)
for the manufacture of CT materials • To discuss the role of the QP in Europe and the certification of a site
05/17/2011 HC Chang
The 3rd Drug Information Association China Annual Meeting 19
against European GMPs
• Conducted by:• Director of European Dev QA (QP)
• Observations: • Facility - e.g. building management system • People - e.g. QA staff vs. technical staff • Quality system - e.g. clarity of contents in the SOPs
2nd Quality Due Diligence
• Purpose:• To assess our partner’s readiness to receive a formal QA Audit from
Eli Lilly and Company
• Conducted by:• VP of Quality Assurance API operations/Product R&D
05/17/2011 HC Chang
The 3rd Drug Information Association China Annual Meeting 20
• VP of Chemical Product R&D • Team leader & member from CT manufacturing
• Strengths observed:• Facility cleanliness• Education of staff• Openness & spirit of collaboration• Good Set of equipment for multiple studies• Significant progress since last assessment• Previous successful collaboration on API manufacturing
2nd Quality Due Diligence (cont’d)
• Overall RecommendationShould consider to develop overarching Strategy Documentswhich explain the firm’s approach to key elements of Quality Assurance. This will provide several important advantages:• Improved Assurance of Quality for Patients
05/17/2011 HC Chang
The 3rd Drug Information Association China Annual Meeting 21
– By having a well thought out, documented strategy for key elements of Quality Assurance, the firm can ensure that all elements of the strategy are consistent, and work together to assure quality for patients.
– Also a single strategy document allows the firm to explain the strategy more effectively.
Cross Contamination Prevention
Cleaning Programs
Bioburden Control
Materials Management
Validation Master Plan
2nd Quality Due Diligence (cont’d)
• Example: Prevention of Cross Contamination
One strategy which includes:• HVAC Rationale
– What is rationale for air balance?
G i
05/17/2011 HC Chang
The 3rd Drug Information Association China Annual Meeting 22
• Gowning– Is gowning strategy appropriate?
• People Flow– What controls people moving from room to room?
• Material Flow• Facility Cleaning
Cross Contamination Prevention
Cleaning Programs
Bioburden Control
Materials Management
Validation Master Plan
Continue to Build Quality Mindset with Our Partner
• Two-day Quality System Discussion Forum in Indianapolis
Invited by Exec. Dir. of Global Quality API operations/Product R&D
• To exchange philosophy & experience on quality system and build strong collaboration
• Participants
05/17/2011 HC Chang
The 3rd Drug Information Association China Annual Meeting 23
• Participants – Five of our partner’s quality & technical leaders– Twenty of Lilly quality & technical leaders
• Topics discussed:– Overview of Lilly global and development quality systems – Cleaning approach– Cross contamination– People qualification
Quality System - Partnership Expectations
• Strategically based Quality System which meet regulatory requirements (SFDA, FDA, ICH, EMEA) & the needs of firm’s business
Emphasized again the importance of the quality strategic documents.
05/17/2011 HC Chang
The 3rd Drug Information Association China Annual Meeting 24
• Overarching Quality System strategy and philosophy to provide a foundation for addressing multiple customer requests, reflecting differing priorities and expectations
• Demonstrate through the Quality System how sponsor’s quality expectations are met
• Changes to firm’s Quality System should be consistent with its overall design and construct – effective change management is critical
3rd Quality Due Diligence
• Purpose:• To assess our partner’s readiness to receive a formal QA Audit
from Eli Lilly and Company
• Conducted by:• Director of European Dev QA (QP)
05/17/2011 HC Chang
The 3rd Drug Information Association China Annual Meeting 25
Director of European Dev QA (QP) • Development Quality Representative (US based)
• Observation:• Significant progress since last assessment• SOPs and Quality Strategic documents are in place• Room to improve on material receiving area
• Recommendation:• To proceed with a formal Lilly quality audit
Facilities & Equipment
LaboratoriesQuality
System Based Approach Audit
• The audit focused on: • 21CFR211 & EU GMP’s • Quality System• Production System
F iliti d E i t S t
05/17/2011 HC Chang
The 3rd Drug Information Association China Annual Meeting 26
Production Materials
Packaging & Labeling
• Facilities and Equipment System• Laboratory Control System • Material System• Packaging & Labeling
• The audit team included: • 3 QA representatives from US
• 1 QP from EU
Summary
• We appreciate our partner’s spirit of collaboration and strong commitments to improve their quality system.
• The overall progress our partner have made on
05/17/2011 HC Chang
The 3rd Drug Information Association China Annual Meeting 27
p g ptheir quality system is very encouraging.
• We will continue to work with our partner to ensure the clinical materials manufactured at their CT facility will be meeting global regulatory requirement and safe for patients.
05/17/2011 HC Chang
The 3rd Drug Information Association China Annual Meeting 28
Thank you!Please send you questions to [email protected]